Clinical trial

Lapatinib in Treating Patients With Recurrent and/or Metastatic Head and Neck…

NCT00098631 · National Cancer Institute (NCI), NIH · Completed

Key facts

NCT number NCT00098631
Title Lapatinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer
Official title A Phase II Study Of GW572016 In Squamous Cell Carcinoma Of The Head And Neck (SCCHN)
Lead sponsor National Cancer Institute (NCI), NIH
Status Completed
Phase Phase 2
Study type Interventional
Conditions Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Salivary Gland Squamous Cell Carcinoma, Stage IV Squamous Cell Carcinoma of the Hypopharynx and 6 more
Intervention type Drug, Other
Interventions lapatinib ditosylate, laboratory biomarker analysis
Enrollment 88
Start date Oct 1, 2004
Primary completion Dec 1, 2006
First posted Dec 8, 2004
Last update posted Jan 7, 2014
Countries United States

At a glance

  • 1–9 Study sites
  • No Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies